MIRM
$100.96
+$2.27 (2.30%)+2.30%
OpenLoading chart...
IndexN/A
Market Cap6.16B
Enterprise Value3.99B
Income$-0.01B
Sales$0.11B
EmployeesN/A
P/E-6.94
P/S7.61
P/B12.60
P/C72.26
EV/EBITDA231.78
EV/SalesN/A
EPS (ttm)-14.55
EarningsN/A
Gross Margin80.71%
Oper. Margin-4.25%
Profit Margin-4.48%
Volume0.35M
Shs Outstand0.06B
Change2.28%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $336.89M | $186.37M | $77.06M | $19.14M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $81.64M | $47.04M | $12.37M | $1.90M | $623.00K | $324.00K | $0.00 |
| Gross Profit | $255.25M | $139.34M | $64.69M | $17.23M | $-623.00K | $-324.00K | $0.00 |
| Gross Margin | 75.77% | 74.76% | 83.94% | 90.06% | N/A | N/A | N/A |
| Operating Expenses | $342.85M | $248.49M | $195.91M | $190.65M | $103.67M | $54.42M | $2.92M |
| Operating Income | $-87.61M | $-109.15M | $-131.22M | $-173.41M | $-104.30M | $-54.74M | $-2.92M |
| Operating Margin | -26.00% | -58.57% | -170.28% | -906.12% | N/A | N/A | N/A |
| Net Income | $-87.94M | $-163.41M | $-135.66M | $-83.99M | $-103.27M | $-52.55M | $-17.35M |
| Net Margin | -26.10% | -87.68% | -176.05% | -438.85% | N/A | N/A | N/A |
| EPS (Basic) | $-1.85 | $-4.00 | $-4.01 | $-2.77 | $-4.09 | $-2.29 | $-0.75 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $670.75M | $646.62M | $352.91M | $294.65M | $240.86M | $146.71M | $51.98M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $445.11M | $397.95M | $210.87M | $174.44M | $68.77M | $16.36M | $62.30M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $225.64M | $248.67M | $142.04M | $120.21M | $172.09M | $130.35M | $-10.32M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $225.64M | $248.67M | $142.04M | $120.21M | $172.09M | $130.35M | $-10.32M |
| Total Liabilities & Stockholders Equity | $670.75M | $646.62M | $352.91M | $294.65M | $240.86M | $146.71M | $51.98M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Net Income | $-87.94M | $-163.41M | $-135.66M | $-83.99M | $-103.27M | $-52.55M | $-17.35M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $10.32M | $-70.94M | $-120.14M | $-132.76M | $-89.08M | $-39.36M | $-373.00K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Arcutis Expands Board of Directors with Appointment of Chris PeetzGlobeNewswire Inc. Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026The Motley Fool XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business AchievementsGlobeNewswire Inc. Is Mirum Pharmaceuticals on a Strong Path to Profitability?The Motley Fool Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the LineThe Motley Fool Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026The Motley Fool Mirum (MIRM) Soars on Interim Data From Liver Disease StudiesZacks Investment Research Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?Zacks Investment Research
Show 12 more stories
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?Zacks Investment Research Mirum's (MIRM) Livmarli Aids Sales but Overdependence ConcernsZacks Investment Research Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of EstimatesZacks Investment Research Analyst Ratings For Mirum PharmaceuticalsBenzinga Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?Zacks Investment Research Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research Some Bubbles Are Starting To PopSeeking Alpha Analyst Ratings For Mirum PharmaceuticalsBenzinga Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?Zacks Investment Research $5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are BuyingBenzinga Cracking The Code: Understanding Analyst Reviews For Mirum PharmaceuticalsBenzinga Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded UseZacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Discover more
You may be interested in